Show simple item record

dc.contributor.authorHacıoğlu, Muhammet Bekir
dc.contributor.authorKöstek, Osman
dc.contributor.authorKarabulut, Senem
dc.contributor.authorTaştekin, Didem
dc.contributor.authorSezgin Göksu, Sema
dc.contributor.authorAlandağ, Celal
dc.contributor.authorAkagündüz, Baran
dc.contributor.authorBilgetekin, İrem
dc.contributor.authorCaner, Burcu
dc.contributor.authorŞahin, Ahmet Bilgehan
dc.contributor.authorYıldız, Birol
dc.contributor.authorKöse, Fatih
dc.date.accessioned2021-06-21T10:32:41Z
dc.date.available2021-06-21T10:32:41Z
dc.date.issued2020en_US
dc.identifier.issn11070625
dc.identifier.urihttps://hdl.handle.net/20.500.12451/8126
dc.description*Sezgin Göksu, Sema ( Aksaray, Yazar )en_US
dc.description.abstractPurpose: After failure of the first-line sorafenib treatment in advanced or metastatic stage hepatocellular carcinoma (HCC), regorafenib is one of the newly-approved targeted agents. We aimed to evaluate the efficacy of regorafenib in patients with advanced HCC treated in the second- or third-line setting. Methods: In this retrospective and multicenter study, advanced HCC patients not eligible for local therapies, who received a second- or third-line regorafenib therapy after progression on the first-line sorafenib or sequential therapy with chemotherapy (CT) followed by sorafenib, were included. Results: In the first-line setting, 28 (28.9%) patients received CT and 69 (71.1%) patients received sorafenib. There were 24 (24.7%) patients who were intolerant to sorafenib. Disease control rate (DCR) was 53.6% for all patients treated with regorafenib, 62.3% in patients who received regorafenib in the second-line, and 32.1% for those receiving regorafenib in the third-line (p=0.007). Median progression-free survival (PFS) and overall survival (OS) were 5.6 (range; 4.3-6.9) and 8.8 (range, 6.3-11.3) months for all patients treated with regorafenib vs. 7.1 months and 10.3 months for patients who received regorafenib in the second-line vs. 5.1 and 8.7 months for patients who received regorafenib in the third-line, respectively; however, there was no statistically significant difference (pPFS=0.22 and pOS=0.85). Conclusion: Although receiving CT as a first-line therapy in advanced HCC patients did not affect the survival rates of subsequent regorafenib therapy, it might diminish the DCR of regorafenib.en_US
dc.language.isoengen_US
dc.publisherZerbinis Publicationsen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectAnti-VEGFtherapyen_US
dc.subjectChemotherapyen_US
dc.subjectDisease Controlrateen_US
dc.subjectHepatocellular Carcinomaen_US
dc.subjectOverallsurvivalen_US
dc.subjectRegorafeniben_US
dc.titleEfficacy of regorafenib in the second-and third-line setting for patients with advanced hepatocellular carcinoma: A real life data of multicenter study from Turkeyen_US
dc.typearticleen_US
dc.relation.journalJournal of B.U.ON.en_US
dc.contributor.departmentTıp Fakültesien_US
dc.contributor.authorID0000-0002-7846-0870en_US
dc.contributor.authorID0000-0002-0156-5973en_US
dc.identifier.volume25en_US
dc.identifier.issue4en_US
dc.identifier.startpage1897en_US
dc.identifier.endpage1903en_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record